<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="of viral infection, and clinical impact was portrayed. SARS-CoV-2 remdesivir" exact="chloroquine" post="hydroxychloroquine lopinavir/ritonavir convalescent plasma 1. Introduction Since the beginning"/>
 <result pre="viral infection, and clinical impact was portrayed. SARS-CoV-2 remdesivir chloroquine" exact="hydroxychloroquine" post="lopinavir/ritonavir convalescent plasma 1. Introduction Since the beginning of"/>
 <result pre="protein (IP10), monocyte chemoattractant protein (MCP1), macrophage inflammatory protein 1" exact="alpha" post="(MIP1A), platelet derived growth factor (PDGF), tumor necrosis factor"/>
 <result pre="selected for the SOLIDARITY trial: remdesivir (RDV), an experimental antiviral;" exact="chloroquine" post="(CQ), an antimalarial agent (or hydroxychloroquineâ€&quot;HCQ); a combination of"/>
 <result pre="chloroquine (CQ), an antimalarial agent (or hydroxychloroquineâ€&quot;HCQ); a combination of" exact="lopinavir" post="and ritonavir (LPV/r), an anti-HIV medication; and lopinavir +"/>
 <result pre="an antimalarial agent (or hydroxychloroquineâ€&quot;HCQ); a combination of lopinavir and" exact="ritonavir" post="(LPV/r), an anti-HIV medication; and lopinavir + ritonavir +"/>
 <result pre="combination of lopinavir and ritonavir (LPV/r), an anti-HIV medication; and" exact="lopinavir" post="+ ritonavir + interferon-beta (an antiviral and modulator of"/>
 <result pre="lopinavir and ritonavir (LPV/r), an anti-HIV medication; and lopinavir +" exact="ritonavir" post="+ interferon-beta (an antiviral and modulator of the immune"/>
 <result pre="to fill the gaps in the RDV toxicological profile. 3.2." exact="Chloroquine" post="and Hydroxychloroquine Chloroquine (CQâ€&quot;Figure 7A, see brief description in"/>
 <result pre="the gaps in the RDV toxicological profile. 3.2. Chloroquine and" exact="Hydroxychloroquine" post="Chloroquine (CQâ€&quot;Figure 7A, see brief description in Table 2),"/>
 <result pre="gaps in the RDV toxicological profile. 3.2. Chloroquine and Hydroxychloroquine" exact="Chloroquine" post="(CQâ€&quot;Figure 7A, see brief description in Table 2), a"/>
 <result pre="been recently reported as a potential broad-spectrum antiviral drug [61,81]." exact="Hydroxychloroquine" post="(HCQâ€&quot;Figure 7B, see brief description in Table 2) is"/>
 <result pre="(HCQâ€&quot;Figure 7B, see brief description in Table 2) is a" exact="chloroquine" post="analogue [82], one of the antimalarials and other anti-inflammatory"/>
 <result pre="SARS-CoV-2 protein targets. Among the results, the authors showed that" exact="chloroquine" post="can target nonstructural proteins such as Nsp3b, exhibiting suitable"/>
 <result pre="was not statistically relevant [92]; (ii) coadministration of HCQ with" exact="azithromycin" post="determined the decrease of viral load in COVID-19 patients"/>
 <result pre="healthcare Israelian database analysis) [97]. The association of HCQ and" exact="azithromycin" post="for the treatment COVID-19 patients was based on several"/>
 <result pre="for the treatment COVID-19 patients was based on several premises:" exact="azithromycin" post="proved in vitro activity against Ebola and Zika viruses,"/>
 <result pre="[93], but further studies confirmed the efficacy of HCQ and" exact="azithromycin" post="combination [98]. CQ and HCQ are also evaluated in"/>
 <result pre="should be noted that melanin-containing cells bind strongly to the" exact="chloroquine" post="process, explaining the retinal toxicity of both compounds [82,90]."/>
 <result pre="are not considered robust [102], and EMA did not approve" exact="chloroquine" post="for standard use in COVID-19 pathology and restricted its"/>
 <result pre="by WHO on 17 June 2020 regarding the assessment of" exact="hydroxychloroquine" post="as a treatment for COVID-19 infection notifies that this"/>
 <result pre="was suspended based on the evidence gathered according to which" exact="hydroxychloroquine" post="had no impact on decreasing the mortality of hospitalized"/>
 <result pre="which also stopped their study [107]. 3.3. Lopinavir/Ritonavir Lopinavir and" exact="ritonavir" post="(LPV/r) (Figure 8, see brief description in Table 2)"/>
 <result pre="with the best scores for potential viral protease inhibition were" exact="lopinavir" post="and ritonavir [111]. In accordance with previous studies, to"/>
 <result pre="best scores for potential viral protease inhibition were lopinavir and" exact="ritonavir" post="[111]. In accordance with previous studies, to investigate a"/>
 <result pre="COVID-19 to test the efficacy and safety of the oral" exact="lopinavir" post="(400 mg) associated with ritonavir (200 mg) in SARS-CoV-2"/>
 <result pre="and safety of the oral lopinavir (400 mg) associated with" exact="ritonavir" post="(200 mg) in SARS-CoV-2 infection. At the end of"/>
 <result pre="parameters: (1) a good absorption rate after oral administration, (2)" exact="lopinavir" post="presents a high affinity for serum proteins (98â€&quot;99% bound"/>
 <result pre="proteins, mainly of alpha-1-acid glycoprotein (AAG)), (3) hepatic biotransformation of" exact="lopinavir" post="is almost exclusively by isozyme CYP3A (ritonavir is a"/>
 <result pre="(iv) rare: Stevensâ€&quot;Johnson syndrome and erythema multiforme [114]. As both" exact="lopinavir" post="and ritonavir are CYP3A enzyme inhibitors, multiple drugâ€&quot;drug interactions"/>
 <result pre="Stevensâ€&quot;Johnson syndrome and erythema multiforme [114]. As both lopinavir and" exact="ritonavir" post="are CYP3A enzyme inhibitors, multiple drugâ€&quot;drug interactions were described,"/>
 <result pre="triazolam, cisapride, domperidone, sirolimus, lovastatin, simvastatin, budesonide, fluticasone, mometasone, and" exact="triamcinolone" post="[114]. In light of the toxicological profile of LPV/r"/>
 <result pre="effects after the lopinavir/ritonavir treatment and 37 patients (17.1%) after" exact="chloroquine" post="use. The adverse effects related to LPV/r use consisted"/>
 <result pre="via hydrogen and hydrophobic bonds, manifesting a synergistic activity with" exact="lopinavir" post="and ritonavir. The authors concluded that the effect of"/>
 <result pre="oseltamivir may be a safe candidate for clinical testing. 4.2." exact="Ribavirin" post="Ribavirin (Figure 11) is a nucleoside analog antiviral agent."/>
 <result pre="may be a safe candidate for clinical testing. 4.2. Ribavirin" exact="Ribavirin" post="(Figure 11) is a nucleoside analog antiviral agent. Structurally,"/>
 <result pre="Ribavirin (Figure 11) is a nucleoside analog antiviral agent. Structurally," exact="ribavirin" post="was modified so that the nucleobase part was replaced"/>
 <result pre="a carboxamide group in the third position. ADME profile wise," exact="ribavirin" post="is a highly soluble, highly polar rigid molecule, suited"/>
 <result pre="mechanism of action, after being metabolized to its triphosphate form," exact="ribavirin" post="competes with the physiological nucleoside (adenosine/guanosine) for the RdRp"/>
 <result pre="infection [124]. Using docking experiments, a research team demonstrated that" exact="ribavirin" post="and other FDA-approved antiviral drugs (galidesivir, remdesivir, tenofovir, sofosbuvir)"/>
 <result pre="conducted in order to explore the specific antiviral activity of" exact="Ribavirin" post="against SARS-CoV-2; the results concluded that high concentrations of"/>
 <result pre="the viral infection, as the EC50 value (109.50 Î¼M) of" exact="ribavirin" post="was higher than that of other antivirals such as"/>
 <result pre="natural compounds and comparable to some FDA-approved drugs such as" exact="nelfinavir" post="and lopinavir [133]. Betulinic acid (3Î²-hydroxy-lup-20(29)-en-28-oic acidâ€&quot;Figure 13) (BA)"/>
 <result pre="and comparable to some FDA-approved drugs such as nelfinavir and" exact="lopinavir" post="[133]. Betulinic acid (3Î²-hydroxy-lup-20(29)-en-28-oic acidâ€&quot;Figure 13) (BA) is a"/>
 <result pre="Î©-undecanoic amides and ionic derivatives of betulinic acid conjugated with" exact="glycine" post="intervene during the fusion of the virus to the"/>
 <result pre="classes able to reduce inflammation include non-steroidal anti-inflammatory medication, glucocorticoids," exact="chloroquine" post="and hydroxychloroquine, immunosuppressants, and inflammatory cytokines antagonists (IL-6R monoclonal"/>
 <result pre="includes the inhibition of enzymes involved in the clathrin-mediated endocytosis;" exact="tofacitinib" post="is an example of drug that produces no inhibition"/>
 <result pre="already associated with known drugs such as nimesulide, didanosine, thiabendazole," exact="fluticasone" post="propionate, and Photofrin, and their role as a key"/>
 <result pre="drugs, tocilizumab should not be administered with the following agents:" exact="metamizole" post="(high risk of hematological toxicity), immunosuppressants (adalimumab and basiliximab),"/>
 <result pre="with other investigated agents for COVID-19 therapy such as chloroquine," exact="hydroxychloroquine" post="(potential additive toxicity), and ribavirin (risk of hematological toxicity)"/>
 <result pre="COVID-19 therapy such as chloroquine, hydroxychloroquine (potential additive toxicity), and" exact="ribavirin" post="(risk of hematological toxicity) requires close monitoring and possible"/>
 <result pre="the subcutaneous use of INF beta-1a in combination therapy with" exact="hydroxychloroquine" post="and lopinavir/ritonavir. The early results showed a positive response"/>
 <result pre="clinical impact of the triple combination, IFN beta-1b, lopinavirâ€&quot;ritonavir, and" exact="ribavirin" post="[155]. The authors showed that treatment with the triple"/>
 <result pre="drug interactions study developed by Liverpool University, both heparin and" exact="argatroban" post="are not susceptible to determine interactions with the investigational"/>
 <result pre="the administration of this compound should be performed under surveillance." exact="Chloroquine" post="and hydroxychloroquine are recommended for compassionate use in mild-to-moderate"/>
 <result pre="of this compound should be performed under surveillance. Chloroquine and" exact="hydroxychloroquine" post="are recommended for compassionate use in mild-to-moderate (as single"/>
 <result pre="adverse events and drugâ€&quot;drug interactions, the significance was reached (both" exact="lopinavir" post="and ritonavir are CYP3A inhibitors and are subjected to"/>
 <result pre="and drugâ€&quot;drug interactions, the significance was reached (both lopinavir and" exact="ritonavir" post="are CYP3A inhibitors and are subjected to multiple drugâ€&quot;drug"/>
 <result pre="Remdesivir for Treating SARS-CoV-2 InfectionsInt. J. Antimicrob. Agents20205510593310.1016/j.ijantimicag.2020.10593332147516 61.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="Chloroquine" post="Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in"/>
 <result pre="online: https://www.covid19-druginteractions.org/(accessed on 25 April 2020) 81.HuT.Y.FriemanM.WolframJ.Insights from Nanomedicine into" exact="Chloroquine" post="Efficacy Against COVID-19Nat. Nanotechnol.20201524724910.1038/s41565-020-0674-932203437 82.YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.LiuX.ZhaoL.DongE.SongC.et al.Optimized Dosing Design of"/>
 <result pre="Chloroquine Efficacy Against COVID-19Nat. Nanotechnol.20201524724910.1038/s41565-020-0674-932203437 82.YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.LiuX.ZhaoL.DongE.SongC.et al.Optimized Dosing Design of" exact="Hydroxychloroquine" post="for the Treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
 <result pre="March 2020Available online: http://arxiv.org/abs/2003.10642(accessed on 25 April 2020) 85.ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int. J. Antimicrob. Agents20205510593210.1016/j.ijantimicag.2020.10593232145363"/>
 <result pre="April 2020) 91.ChowdhuryM.S.RathodJ.GernsheimerJ.A Rapid Systematic Review of Clinical Trials Utilizing" exact="Chloroquine" post="and Hydroxychloroquine as a Treatment for COVID-19Acad. Emerg. Med.202010.1111/acem.14005"/>
 <result pre="91.ChowdhuryM.S.RathodJ.GernsheimerJ.A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and" exact="Hydroxychloroquine" post="as a Treatment for COVID-19Acad. Emerg. Med.202010.1111/acem.14005 92.ChenJ.LiuD.LiuL.LiuP.XuQ.XiaL.LingY.HuangD.SongS.ZhangD.et al.A"/>
 <result pre="Treatment for COVID-19Acad. Emerg. Med.202010.1111/acem.14005 92.ChenJ.LiuD.LiuL.LiuP.XuQ.XiaL.LingY.HuangD.SongS.ZhangD.et al.A Pilot Study of" exact="Hydroxychloroquine" post="in Treatment of Patients with Moderate COVID-19Zhejiang Da Xue"/>
 <result pre="Da Xue Xue Bao Yi Xue Ban20204921521932391667 93.GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and" exact="Azithromycin" post="as a Treatment of COVID-19: Results of an Open-Label"/>
 <result pre="of an Open-Label Non-Randomized Clinical TrialInt. J. Antimicrob. Agents202010594910.1016/j.ijantimicag.2020.10594932205204 94.GaoJ.TianZ.YangX.Breakthrough:" exact="Chloroquine" post="Phosphate Has Shown Apparent Efficacy in Treatment of COVID-19"/>
 <result pre="StudiesBiosci. Trends202014727310.5582/bst.2020.0104732074550 95.ZhouD.DaiS.M.TongQ.COVID-19: A Recommendation to Examine the Effect of" exact="Hydroxychloroquine" post="in Preventing Infection and ProgressionJ. Antimicrob. Chemother.202010.1093/jac/dkaa114 96.MeoS.A.KlonoffD.C.AkramJ.Efficacy of"/>
 <result pre="Hydroxychloroquine in Preventing Infection and ProgressionJ. Antimicrob. Chemother.202010.1093/jac/dkaa114 96.MeoS.A.KlonoffD.C.AkramJ.Efficacy of" exact="Chloroquine" post="and Hydroxychloroquine in the Treatment of COVID-19Eur. Rev. Med."/>
 <result pre="Preventing Infection and ProgressionJ. Antimicrob. Chemother.202010.1093/jac/dkaa114 96.MeoS.A.KlonoffD.C.AkramJ.Efficacy of Chloroquine and" exact="Hydroxychloroquine" post="in the Treatment of COVID-19Eur. Rev. Med. Pharmacol. Sci.2020244539454710.26355/eurrev_202004_2103832373993"/>
 <result pre="in the Treatment of COVID-19Eur. Rev. Med. Pharmacol. Sci.2020244539454710.26355/eurrev_202004_2103832373993 97.GendelmanO.AmitalH.BragazziN.L.WatadA.ChodickG.Continuous" exact="Hydroxychloroquine" post="or Colchicine Therapy Does Not Prevent Infection with SARS-CoV-2:"/>
 <result pre="Large Healthcare Database AnalysisAutoimmun. Rev.202010256610.1016/j.autrev.2020.10256632380315 98.SunJ.ChenY.FanX.WangX.HanQ.LiuZ.Advances in the Use of" exact="Chloroquine" post="and Hydroxychloroquine for the Treatment of COVID-19Postgrad. Med.202010.1080/00325481.2020.177898232496926 99.ShuklaA.M.ArchibaldL.K.ShuklaA.W.MehtaH.J.CherabuddiK.Chloroquine"/>
 <result pre="Database AnalysisAutoimmun. Rev.202010256610.1016/j.autrev.2020.10256632380315 98.SunJ.ChenY.FanX.WangX.HanQ.LiuZ.Advances in the Use of Chloroquine and" exact="Hydroxychloroquine" post="for the Treatment of COVID-19Postgrad. Med.202010.1080/00325481.2020.177898232496926 99.ShuklaA.M.ArchibaldL.K.ShuklaA.W.MehtaH.J.CherabuddiK.Chloroquine and Hydroxychloroquine"/>
 <result pre="and Hydroxychloroquine for the Treatment of COVID-19Postgrad. Med.202010.1080/00325481.2020.177898232496926 99.ShuklaA.M.ArchibaldL.K.ShuklaA.W.MehtaH.J.CherabuddiK.Chloroquine and" exact="Hydroxychloroquine" post="in the Context of COVID-19Drugs Context2020910.7573/dic.2020-4-5 100.Van den EyndeJ.J.COVID-19:"/>
 <result pre="EyndeJ.J.COVID-19: An Update about the Discovery Clinical TrialPharmaceuticals2020139810.3390/ph13050098 101.PastickK.A.OkaforE.C.WangF.LofgrenS.M.SkipperC.P.NicolM.R.PullenM.F.RajasinghamR.McDonaldE.G.LeeT.C.et al.Review:" exact="Hydroxychloroquine" post="and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)Open Forum Infect."/>
 <result pre="Update about the Discovery Clinical TrialPharmaceuticals2020139810.3390/ph13050098 101.PastickK.A.OkaforE.C.WangF.LofgrenS.M.SkipperC.P.NicolM.R.PullenM.F.RajasinghamR.McDonaldE.G.LeeT.C.et al.Review: Hydroxychloroquine and" exact="Chloroquine" post="for Treatment of SARS-CoV-2 (COVID-19)Open Forum Infect. Dis.2020710.1093/ofid/ofaa130 102.MeyerowitzE.A.VannierA.FriesenM.SchoenfeldS.GelfandJ.A.CallahanM.V.KimA.Y.ReevesP.M.PoznanskyM.C.Rethinking"/>
 <result pre="of SARS-CoV-2 (COVID-19)Open Forum Infect. Dis.2020710.1093/ofid/ofaa130 102.MeyerowitzE.A.VannierA.FriesenM.SchoenfeldS.GelfandJ.A.CallahanM.V.KimA.Y.ReevesP.M.PoznanskyM.C.Rethinking the Role of" exact="Hydroxychloroquine" post="in the Treatment of COVID-19FASEB J.2020346027603710.1096/fj.20200091932350928 103.RuamviboonsukP.LaiT.ChangA.LaiC.C.MielerW.F.LamD.collab: Asia-Pacific Vitreo-Retina"/>
 <result pre="the Treatment of COVID-19FASEB J.2020346027603710.1096/fj.20200091932350928 103.RuamviboonsukP.LaiT.ChangA.LaiC.C.MielerW.F.LamD.collab: Asia-Pacific Vitreo-Retina SocietyChloroquine and" exact="Hydroxychloroquine" post="Retinal Toxicity Consideration in the Treatment of COVID-19Asia Pac."/>
 <result pre="in a patient with coronavirus disease 2019Heart Rhythm2020304203042310.1016/j.hrthm.2020.04.04632380291 106.collab: EMACOVID-19:" exact="Chloroquine" post="and Hydroxychloroquine Only to be Used in Clinical Trials"/>
 <result pre="patient with coronavirus disease 2019Heart Rhythm2020304203042310.1016/j.hrthm.2020.04.04632380291 106.collab: EMACOVID-19: Chloroquine and" exact="Hydroxychloroquine" post="Only to be Used in Clinical Trials or Emergency"/>
 <result pre="Studies of Drug Repurposing and Synergism of Lopinavir, Oseltamivir and" exact="Ritonavir" post="Binding with SARS-CoV-2 Protease against COVID-19J. Biomol. Struct. Dyn.202010.1080/07391102.2020.175280232248766"/>
 <result pre="Antimicrob. Chemother.20106510.1093/jac/dkq015 123.ThomasE.GhanyM.G.LiangT.J.Review the application and mechanism of action of" exact="ribavirin" post="in therapy of hepatitis CAntivir. Chem. Chemother.20122311210.3851/IMP212522592135 124.ElfikyA.A.Anti-HCV, nucleotide"/>
 <result pre="TrialInt. Immunopharmacol.20208510668810.1016/j.intimp.2020.10668832544867 155.HungI.F.N.LungK.C.TsoE.Y.K.LiuR.ChungT.W.H.ChuM.Y.NgY.Y.LoJ.ChanJ.TamA.R.et al.Triple Combination of Interferon Beta-1b, Lopinavir-Ritonavir, and" exact="Ribavirin" post="in the Treatment of Patients Admitted to Hospital with"/>
 <result pre="green, and nucleotides in orange. Figure 7 Chemical structure of" exact="chloroquine" post="(A) and hydroxychloroquine (B) ADME profile was achieved using"/>
 <result pre="in orange. Figure 7 Chemical structure of chloroquine (A) and" exact="hydroxychloroquine" post="(B) ADME profile was achieved using the free web"/>
 <result pre="nausea, pain in the extremities elevation of hepatic enzymes values" exact="Chloroquine" post="(CQ) 4-aminoquinoline Mild-to-moderate and severeâ€&quot;depending on the guideline applied"/>
 <result pre="adverse effects have a lower intensity, but are not absent" exact="Hydroxychloroquine" post="(HCQ) 4-aminoquinoline Mild-to-moderate and severeâ€&quot;depending on the guideline applied"/>
</results>
